{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:33:18Z","timestamp":1768735998069,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T00:00:00Z","timestamp":1134345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T00:00:00Z","timestamp":1134345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-positive (ER+) breast cancer cells.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We examined the anti-proliferative properties of ibandronate on two ER+ breast cancer cell lines (MCF-7 and IBEP-2), and on one ER negative (ER-) cell line (MDA-MB-231). Experiments were performed in steroid-free medium to assess ER regulation and the effect of ibandronate in combination with estrogen or antiestrogens.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Ibandronate inhibited cancer cell growth in a dose- and time-dependent manner (approximate IC<jats:sub>50<\/jats:sub>: 10<jats:sup>-4<\/jats:sup> M for MCF-7 and IBEP-2 cells; 3 \u00d7 10<jats:sup>-4<\/jats:sup> M for MDA-MB-231 cells), partly through apoptosis induction. It completely abolished the mitogenic effect induced by 17\u03b2-estradiol in ER+ breast cancer cells, but affected neither ER regulation nor estrogen-induced progesterone receptor expression, as documented in MCF-7 cells. Moreover, ibandronate enhanced the growth inhibitory action of partial (4-hydroxytamoxifen) and pure (ICI 182,780, now called fluvestrant or Faslodex\u2122) antiestrogens in estrogen-sensitive breast cancer cells. Combination analysis identified additive interactions between ibandronate and ER antagonists.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>These data constitute the first <jats:italic>in vitro<\/jats:italic> evidence for additive effects between ibandronate and antiestrogens, supporting their combined use for the treatment of bone metastases from breast cancer.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr1363","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T07:27:15Z","timestamp":1134458835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines"],"prefix":"10.1186","volume":"8","author":[{"given":"Fabrice","family":"Journe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Chaboteaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Magne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Duvillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"issue":"Suppl 1","key":"1342_CR1","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S8756-3282(09)80011-2","volume":"13","author":"JJ Body","year":"1992","unstructured":"Body JJ: Metastatic bone disease: clinical and therapeutic aspects. Bone. 1992, 13 (Suppl 1): S57-62.","journal-title":"Bone"},{"issue":"8 Suppl","key":"1342_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE: Skeletal complications of malignancy. Cancer. 1997, 80 (8 Suppl): 1588-1594. 10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G.","journal-title":"Cancer"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF01975440","volume":"18","author":"PG Koenders","year":"1991","unstructured":"Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ: Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat. 1991, 18: 27-32. 10.1007\/BF01975440.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"1342_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/8756-3282(91)90057-P","volume":"12","author":"GR Mundy","year":"1991","unstructured":"Mundy GR: Mechanisms of osteolytic bone destruction. Bone. 1991, 12 (Suppl 1): S1-6. 10.1016\/8756-3282(91)90057-P.","journal-title":"Bone"},{"issue":"Suppl 2","key":"1342_CR5","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0960-9776(03)80162-5","volume":"12","author":"JJ Body","year":"2003","unstructured":"Body JJ: Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast. 2003, 12 (Suppl 2): S37-44. 10.1016\/S0960-9776(03)80162-5.","journal-title":"Breast"},{"key":"1342_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev. 1998, 19: 80-100. 10.1210\/er.19.1.80.","journal-title":"Endocr Rev"},{"key":"1342_CR7","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","volume":"16","author":"JJ Body","year":"1998","unstructured":"Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, et al: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998, 16: 3890-3899.","journal-title":"J Clin Oncol"},{"key":"1342_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199808063390609","volume":"339","author":"GR Mundy","year":"1998","unstructured":"Mundy GR, Yoneda T: Bisphosphonates as anticancer drugs. N Engl J Med. 1998, 339: 398-400. 10.1056\/NEJM199808063390609.","journal-title":"N Engl J Med"},{"key":"1342_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998, 13: 581-589.","journal-title":"J Bone Miner Res"},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","volume":"25","author":"RG Russell","year":"1999","unstructured":"Russell RG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999, 25: 97-106. 10.1016\/S8756-3282(99)00116-7.","journal-title":"Bone"},{"key":"1342_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","volume":"28","author":"HL Benford","year":"2001","unstructured":"Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001, 28: 465-473. 10.1016\/S8756-3282(01)00412-4.","journal-title":"Bone"},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","volume":"15","author":"O Fromigue","year":"2000","unstructured":"Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000, 15: 2211-2221.","journal-title":"J Bone Miner Res"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.","journal-title":"Br J Cancer"},{"key":"1342_CR14","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61: 2602-2608.","journal-title":"Cancer Res"},{"key":"1342_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2003.12.012","volume":"45","author":"JC Dumon","year":"2004","unstructured":"Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ: Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol. 2004, 45: 521-528. 10.1016\/j.eururo.2003.12.012. discussion 528\u2013529","journal-title":"Eur Urol"},{"key":"1342_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/sj.bjc.6601009","volume":"89","author":"O Fromigue","year":"2003","unstructured":"Fromigue O, Kheddoumi N, Body JJ: Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer. 2003, 89: 178-184. 10.1038\/sj.bjc.6601009.","journal-title":"Br J Cancer"},{"key":"1342_CR17","first-page":"4418","volume":"61","author":"T Hiraga","year":"2001","unstructured":"Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61: 4418-4424.","journal-title":"Cancer Res"},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/ijc.11397","volume":"107","author":"M Neudert","year":"2003","unstructured":"Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ: Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer. 2003, 107: 468-477. 10.1002\/ijc.11397.","journal-title":"Int J Cancer"},{"key":"1342_CR19","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60: 2949-2954.","journal-title":"Cancer Res"},{"key":"1342_CR20","first-page":"3890","volume":"57","author":"S Boissier","year":"1997","unstructured":"Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997, 57: 3890-3894.","journal-title":"Cancer Res"},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02967634","volume":"10","author":"Y Miyoshi","year":"2003","unstructured":"Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Current status of endocrine therapy for breast cancer. Breast Cancer. 2003, 10: 105-111.","journal-title":"Breast Cancer"},{"key":"1342_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0305-7372(78)80017-6","volume":"5","author":"H Mouridsen","year":"1978","unstructured":"Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978, 5: 131-141.","journal-title":"Cancer Treat Rev"},{"key":"1342_CR23","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51: 3867-3873.","journal-title":"Cancer Res"},{"key":"1342_CR24","first-page":"4309","volume":"9","author":"PF Bross","year":"2003","unstructured":"Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A, et al: Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res. 2003, 9: 4309-4317.","journal-title":"Clin Cancer Res"},{"key":"1342_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","volume":"89","author":"A Howell","year":"2000","unstructured":"Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, \"pure\" antiestrogen. Cancer. 2000, 89: 817-825. 10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6.","journal-title":"Cancer"},{"key":"1342_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0092-8674(88)90552-1","volume":"54","author":"NJ Webster","year":"1988","unstructured":"Webster NJ, Green S, Jin JR, Chambon P: The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell. 1988, 54: 199-207. 10.1016\/0092-8674(88)90552-1.","journal-title":"Cell"},{"key":"1342_CR27","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1093\/nar\/17.14.5477","volume":"17","author":"JA Lees","year":"1989","unstructured":"Lees JA, Fawell SE, Parker MG: Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res. 1989, 17: 5477-5488.","journal-title":"Nucleic Acids Res"},{"key":"1342_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jsbmb.2003.09.011","volume":"87","author":"I Laios","year":"2003","unstructured":"Laios I, Journe F, Laurent G, Nonclercq D, Toillon RA, Seo HS, Leclercq G: Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol. 2003, 87: 207-221. 10.1016\/j.jsbmb.2003.09.011.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1342_CR29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1242\/jcs.106.4.1377","volume":"106","author":"S Dauvois","year":"1993","unstructured":"Dauvois S, White R, Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993, 106: 1377-1388.","journal-title":"J Cell Sci"},{"key":"1342_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jsbmb.2005.02.005","volume":"94","author":"I Laios","year":"2005","unstructured":"Laios I, Journe F, Nonclercq D, Vidal DS, Toillon RA, Laurent G, Leclercq G: Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol. 2005, 94: 347-359. 10.1016\/j.jsbmb.2005.02.005.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1342_CR31","first-page":"4355","volume":"47","author":"BS Katzenellenbogen","year":"1987","unstructured":"Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 1987, 47: 4355-4360.","journal-title":"Cancer Res"},{"key":"1342_CR32","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/0006-291X(87)90819-9","volume":"146","author":"F Vignon","year":"1987","unstructured":"Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun. 1987, 146: 1502-1508. 10.1016\/0006-291X(87)90819-9.","journal-title":"Biochem Biophys Res Commun"},{"key":"1342_CR33","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/sj.emboj.7600231","volume":"23","author":"S Wang","year":"2004","unstructured":"Wang S, Zhang B, Faller DV: BRG1\/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J. 2004, 23: 2293-2303. 10.1038\/sj.emboj.7600231.","journal-title":"EMBO J"},{"key":"1342_CR34","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1210\/me.2003-0278","volume":"18","author":"MB Buck","year":"2004","unstructured":"Buck MB, Pfizenmaier K, Knabbe C: Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol. 2004, 18: 1643-1657. 10.1210\/me.2003-0278.","journal-title":"Mol Endocrinol"},{"key":"1342_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<677::AID-IJC11>3.0.CO;2-1","volume":"76","author":"B Siwek","year":"1998","unstructured":"Siwek B, Larsimont D, Lacroix M, Body JJ: Establishment and characterization of three new breast-cancer cell lines. Int J Cancer. 1998, 76: 677-683. 10.1002\/(SICI)1097-0215(19980529)76:5<677::AID-IJC11>3.0.CO;2-1.","journal-title":"Int J Cancer"},{"key":"1342_CR36","first-page":"5883","volume":"47","author":"N Devleeschouwer","year":"1987","unstructured":"Devleeschouwer N, Legros N, Olea-Serrano N, Paridaens R, Leclercq G: Estrogen conjugates and serum factors mediating the estrogenic trophic effect on MCF-7 cell growth. Cancer Res. 1987, 47: 5883-5887.","journal-title":"Cancer Res"},{"key":"1342_CR37","unstructured":"Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ: Steroid-free medium discloses estrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br J Cancer"},{"key":"1342_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016\/0065-2571(84)90007-4.","journal-title":"Adv Enzyme Regul"},{"key":"1342_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/B:BREA.0000032922.87541.31","volume":"86","author":"F Journe","year":"2004","unstructured":"Journe F, Body JJ, Leclercq G, Nonclercq D, Laurent G: Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma. Breast Cancer Res Treat. 2004, 86: 39-53. 10.1023\/B:BREA.0000032922.87541.31.","journal-title":"Breast Cancer Res Treat"},{"key":"1342_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0303-7207(00)00397-X","volume":"172","author":"A Fazzari","year":"2001","unstructured":"Fazzari A, Catalano MG, Comba A, Becchis M, Raineri M, Frairia R, Fortunati N: The control of progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone-binding globulin (SHBG). Mol Cell Endocrinol. 2001, 172: 31-36. 10.1016\/S0303-7207(00)00397-X.","journal-title":"Mol Cell Endocrinol"},{"issue":"12 Suppl","key":"1342_CR41","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A: Bisphosphonates and breast carcinoma: present and future. Cancer. 2000, 88 (12 Suppl): 3033-3037. 10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C.","journal-title":"Cancer"},{"key":"1342_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejcsup.2004.01.002","volume":"2","author":"JJ Body","year":"2004","unstructured":"Body JJ: Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease. EJC Supplements. 2004, 2: 5-8.","journal-title":"EJC Supplements"},{"key":"1342_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/A:1014795216669","volume":"6","author":"JJ Body","year":"2001","unstructured":"Body JJ: Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia. 2001, 6: 477-485. 10.1023\/A:1014795216669.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1342_CR44","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003, 14: 1399-1405. 10.1093\/annonc\/mdg367.","journal-title":"Ann Oncol"},{"key":"1342_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004, 90: 1133-1137. 10.1038\/sj.bjc.6601663.","journal-title":"Br J Cancer"},{"key":"1342_CR46","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","volume":"22","author":"I Mancini","year":"2004","unstructured":"Mancini I, Dumon JC, Body JJ: Efficacy and safety of ibandronate in the treatment of opoid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol. 2004, 22: 3587-3592. 10.1200\/JCO.2004.07.054.","journal-title":"J Clin Oncol"},{"key":"1342_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84: 1126-1134. 10.1054\/bjoc.2001.1727.","journal-title":"Br J Cancer"},{"key":"1342_CR48","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","volume":"86","author":"SG Senaratne","year":"2002","unstructured":"Senaratne SG, Mansi JL, Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer. 2002, 86: 1479-1486. 10.1038\/sj.bjc.6600297.","journal-title":"Br J Cancer"},{"key":"1342_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/bcr412","volume":"4","author":"SG Senaratne","year":"2002","unstructured":"Senaratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res. 2002, 4: 18-23. 10.1186\/bcr412.","journal-title":"Breast Cancer Res"},{"key":"1342_CR50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S8756-3282(01)00665-2","volume":"30","author":"P Ravn","year":"2002","unstructured":"Ravn P, Neugebauer G, Christiansen C: Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone. 2002, 30: 320-324. 10.1016\/S8756-3282(01)00665-2.","journal-title":"Bone"},{"key":"1342_CR51","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105.","journal-title":"J Clin Invest"},{"key":"1342_CR52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1210\/en.2002-220726","volume":"144","author":"SF Doisneau-Sixou","year":"2003","unstructured":"Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, et al: Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology. 2003, 144: 989-998. 10.1210\/en.2002-220726.","journal-title":"Endocrinology"},{"key":"1342_CR53","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0960-0760(03)00068-2","volume":"84","author":"J Jensen","year":"2003","unstructured":"Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE: Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol. 2003, 84: 469-478. 10.1016\/S0960-0760(03)00068-2.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1342_CR54","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/j.1460-2075.1996.tb00571.x","volume":"15","author":"G Bunone","year":"1996","unstructured":"Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.","journal-title":"EMBO J"},{"key":"1342_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s001090050241","volume":"76","author":"NL Weigel","year":"1998","unstructured":"Weigel NL, Zhang Y: Ligand-independent activation of steroid hormone receptors. J Mol Med. 1998, 76: 469-479. 10.1007\/s001090050241.","journal-title":"J Mol Med"},{"key":"1342_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","volume":"264","author":"E van Beek","year":"1999","unstructured":"van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999, 264: 108-111. 10.1006\/bbrc.1999.1499.","journal-title":"Biochem Biophys Res Commun"},{"key":"1342_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/abbi.1999.1502","volume":"373","author":"JD Bergstrom","year":"2000","unstructured":"Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000, 373: 231-241. 10.1006\/abbi.1999.1502.","journal-title":"Arch Biochem Biophys"},{"key":"1342_CR58","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003, 9: 2643-2658. 10.2174\/1381612033453640.","journal-title":"Curr Pharm Des"},{"key":"1342_CR59","first-page":"3583","volume":"43","author":"CK Osborne","year":"1983","unstructured":"Osborne CK, Boldt DH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983, 43: 3583-3585.","journal-title":"Cancer Res"},{"key":"1342_CR60","first-page":"1433","volume":"44","author":"CK Osborne","year":"1984","unstructured":"Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984, 44: 1433-1439.","journal-title":"Cancer Res"},{"key":"1342_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00689680","volume":"31","author":"CK Watts","year":"1994","unstructured":"Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL: Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1994, 31: 95-105. 10.1007\/BF00689680.","journal-title":"Breast Cancer Res Treat"},{"key":"1342_CR62","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ijc.11263","volume":"106","author":"SF Doisneau-Sixou","year":"2003","unstructured":"Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, Sutherland RL: Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer. 2003, 106: 789-798. 10.1002\/ijc.11263.","journal-title":"Int J Cancer"},{"key":"1342_CR63","first-page":"S59","volume":"34","author":"F Journe","year":"2004","unstructured":"Journe F, Chaboteaux C, Laurent G, Dumon JC, Body JJ: Ibandronate inhibits the proliferation of estrogen receptor-positive breast cancer cells: evidence for additivity with antiestrogens. Bone. 2004, 34: S59-abstract 23","journal-title":"Bone"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr1363\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:00:12Z","timestamp":1728385212000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr1363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,2]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1186\/bcr1363","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,12]]},"assertion":[{"value":"25 May 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R2"}}